In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia

Journal de Mycologie Medicale

Volumn 22, Issue 3, 2012, Pages 243-248

  Trpkovic A ^a,b   Pekmezovic M ^a   Barac A ^a   Crncevic Radovic L ^c   Arsic Arsenijevic V ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Institute of Public Health of Serbia   (Serbia)

Author keywords

Antifungal susceptibility; Azole resistance; Cerebrospinal fluid; Cryptococcus neoformans; E test ; Epidemiology

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD SAMPLING; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; FUNGAL STRAIN; FUNGUS ISOLATION; GRAFT RECIPIENT; HUMAN; IN VITRO STUDY; KIDNEY TRANSPLANTATION; LYMPHOMA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SERBIA;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CEREBROSPINAL FLUID; CROSS INFECTION; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, MULTIPLE, FUNGAL; FLUCONAZOLE; FLUCYTOSINE; FUNGEMIA; HUMANS; ITRACONAZOLE; KIDNEY TRANSPLANTATION; LYMPHOMA; MENINGITIS, CRYPTOCOCCAL; MICROBIAL SENSITIVITY TESTS; POSTOPERATIVE COMPLICATIONS; SERBIA;

FILOBASIDIELLA NEOFORMANS;

EID: 84865787597     PISSN: 11565233     EISSN: 17730449     Source Type: Journal    
DOI: 10.1016/j.mycmed.2012.06.002     Document Type: Article

References (21)

1. ® and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents. J Antimicrob Chemother 2000, 46:997-1000.
2. Andes D., Pascual A., Marchetti O. Established and emerging indications antifungal therapeutic drug monitoring. Antimicrob Agents Chemother 2009, 53:24-34.
3. Arsic V., Mitrovic S., Kranjčiczec I., Džamic A. Isolates of Cryptococcus neoformans serotype A or D from cerebrospinal fluid resistant to 5-fluorocytosine. J Chemother 1995, 7:90-92.
4. Bamba S., Lortholary O., Sawadogo A., Millogo A., Guiguemdé R.T., Bretagne S. Decreasing incidence of cryptococcal meningitis in West Africa in the era of highly active antiretroviral therapy. AIDS 2012, 26:1039-1041.
5. ®: comparison with broth macrodilution technique. J Antimicrob Chemother 1996, 37:265-273.
6. Clinical Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A3 2008, Clinical and Laboratory Standards Institute, Wayne, PA. 3rd ed.
7. Dannaoui E., Abdul M., Arpin M., et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006, 50:2464-2470.
8. Desalermos A., Kourkoumpetis T.K., Mylonakis E. Update on the epidemiology and management of cryptococcal meningitis. Expert Opin Pharmacother 2012, 13:783-789.
9. ® and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates. J Med Microbiol 2006, 55:1693-1699.
10. Hospenthal D.R., Bennett J.E. Flucytosine monotherapy for cryptococcosis. Clin Infect Dis 1998, 27:260-264.
11. ® and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol 1998, 36:2817-2822.
12. Mazuelos E.M., García A.I. Microbiological aspects of the cryptococcosis in the post-HAART era. Enferm Infecc Microbiol Clin. 2010, 28:40-45.
13. Perkins A., Gomez-Lopez A., Mellado E., Rodriguez-Tudela J.L., Cuenca-Estrella M. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 2005, 56:1144-1147.
14. ® method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J Clin Microbiol 1998, 36:2586-2589.
15. Pfaller M.A., Boyken L., Hollis R.J., Messer S.A., Tendolkar S., Diekema D.J. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans and Aspergillus species to itraconazole: global survey of 9359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2005, 43:3807-3810.
16. Pfaller M.A., Messer S.A., Boyken L., et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005, 43:2163-2167.
17. Saag M.S., Cloud G.A., Graybill J.R., et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999, 28:291-296.
18. Sar B., Monchy D., Vann M., Keo C., Sarthou J.L., Buisson Y. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 2004, 54:563-565.
19. ®. Eur J Clin Microbiol Infect Dis 1997, 16:693-697.
20. Tay S.T., Haryanty T.T., Ng K.P., Rohani M.Y., Hamimah H. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs. Mycoses 2006, 49:324-330.
21. Viviani M.A., Esposito M.C., Cogliati M., Tortorano A.M. Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome?. J Chemother 2003, 15:124-128.